Sung Ji Nam
Stock Analyst at Scotiabank
(3.76)
# 742
Out of 5,090 analysts
83
Total ratings
52.17%
Success rate
8.9%
Average return
Main Sectors:
Stocks Rated by Sung Ji Nam
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Sector Outperform | $57 → $60 | $108.75 | -44.83% | 6 | Jul 31, 2025 | |
| TECH Bio-Techne | Maintains: Sector Outperform | $90 → $75 | $63.37 | +18.35% | 3 | Jul 11, 2025 | |
| DHR Danaher | Upgrades: Sector Outperform | $275 | $227.13 | +21.08% | 2 | Jul 11, 2025 | |
| TMO Thermo Fisher Scientific | Upgrades: Sector Outperform | $590 | $575.24 | +2.57% | 15 | Jul 11, 2025 | |
| ILMN Illumina | Downgrades: Sector Perform | $125 | $127.80 | -2.19% | 10 | Jul 11, 2025 | |
| CSTL Castle Biosciences | Maintains: Sector Outperform | $44 → $40 | $39.59 | +1.05% | 6 | May 21, 2025 | |
| BDSX Biodesix | Maintains: Sector Outperform | $60 → $40 | $8.52 | +369.76% | 2 | May 21, 2025 | |
| MYGN Myriad Genetics | Downgrades: Sector Perform | $20 → $6 | $7.31 | -17.86% | 4 | May 21, 2025 | |
| BNGO Bionano Genomics | Maintains: Sector Perform | $1 → $4 | $1.70 | +135.99% | 6 | Apr 2, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Sector Outperform | $6 → $2 | $2.49 | -19.52% | 5 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $73 | $101.15 | -27.83% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $10 → $12 | $17.31 | -30.68% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $430 → $450 | $396.37 | +13.53% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $54 → $62 | $32.39 | +91.42% | 5 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $40 → $44 | $47.41 | -7.19% | 4 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $35 | $19.31 | +81.25% | 4 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $6 | $4.77 | +25.79% | 2 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.29 | - | 3 | Nov 24, 2020 |
Guardant Health
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $57 → $60
Current: $108.75
Upside: -44.83%
Bio-Techne
Jul 11, 2025
Maintains: Sector Outperform
Price Target: $90 → $75
Current: $63.37
Upside: +18.35%
Danaher
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $275
Current: $227.13
Upside: +21.08%
Thermo Fisher Scientific
Jul 11, 2025
Upgrades: Sector Outperform
Price Target: $590
Current: $575.24
Upside: +2.57%
Illumina
Jul 11, 2025
Downgrades: Sector Perform
Price Target: $125
Current: $127.80
Upside: -2.19%
Castle Biosciences
May 21, 2025
Maintains: Sector Outperform
Price Target: $44 → $40
Current: $39.59
Upside: +1.05%
Biodesix
May 21, 2025
Maintains: Sector Outperform
Price Target: $60 → $40
Current: $8.52
Upside: +369.76%
Myriad Genetics
May 21, 2025
Downgrades: Sector Perform
Price Target: $20 → $6
Current: $7.31
Upside: -17.86%
Bionano Genomics
Apr 2, 2025
Maintains: Sector Perform
Price Target: $1 → $4
Current: $1.70
Upside: +135.99%
Pacific Biosciences of California
Mar 25, 2025
Maintains: Sector Outperform
Price Target: $6 → $2
Current: $2.49
Upside: -19.52%
Feb 24, 2025
Maintains: Sector Outperform
Price Target: $70 → $73
Current: $101.15
Upside: -27.83%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $10 → $12
Current: $17.31
Upside: -30.68%
Feb 13, 2025
Upgrades: Sector Outperform
Price Target: $430 → $450
Current: $396.37
Upside: +13.53%
Feb 4, 2025
Maintains: Sector Outperform
Price Target: $54 → $62
Current: $32.39
Upside: +91.42%
Nov 8, 2024
Maintains: Sector Outperform
Price Target: $40 → $44
Current: $47.41
Upside: -7.19%
Nov 5, 2024
Maintains: Buy
Price Target: $40 → $35
Current: $19.31
Upside: +81.25%
Jun 29, 2023
Assumes: Buy
Price Target: $6
Current: $4.77
Upside: +25.79%
Nov 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $28.29
Upside: -